AU651643B2 - Erythrocytes and thrombo-erythrocytes as target specific agents - Google Patents

Erythrocytes and thrombo-erythrocytes as target specific agents

Info

Publication number: AU651643B2
Authority: AU; Australia
Prior art keywords: erythrocyte; thrombo; erythrocytes; molecule; polypeptide
Prior art date: 1990-11-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU90588/91A

Other languages

English (en)

Other versions

AU9058891A (en

Inventor

Barry S Coller

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Research Foundation of the State University of New York

Original Assignee

Research Foundation of the State University of New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-09

Filing date

1991-11-12

Publication date

1994-07-28

1991-11-12 Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York

1992-06-11 Publication of AU9058891A publication Critical patent/AU9058891A/en

1994-07-28 Application granted granted Critical

1994-07-28 Publication of AU651643B2 publication Critical patent/AU651643B2/en

2011-11-12 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

210000003743 erythrocyte Anatomy 0.000 title claims description 331
108090000765 processed proteins & peptides Proteins 0.000 claims description 231
102000004196 processed proteins & peptides Human genes 0.000 claims description 122
238000000034 method Methods 0.000 claims description 74
150000001413 amino acids Chemical class 0.000 claims description 68
235000001014 amino acid Nutrition 0.000 claims description 67
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 65
230000027455 binding Effects 0.000 claims description 58
210000004369 blood Anatomy 0.000 claims description 51
239000008280 blood Substances 0.000 claims description 51
229920001184 polypeptide Polymers 0.000 claims description 47
230000008685 targeting Effects 0.000 claims description 39
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 36
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 35
125000000524 functional group Chemical group 0.000 claims description 34
-1 N-maleimido-6- aminocaproyl ester Chemical class 0.000 claims description 31
125000003396 thiol group Chemical group [H]S* 0.000 claims description 31
241000124008 Mammalia Species 0.000 claims description 30
230000000740 bleeding effect Effects 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 23
108090000623 proteins and genes Proteins 0.000 claims description 22
150000001408 amides Chemical class 0.000 claims description 21
102000004169 proteins and genes Human genes 0.000 claims description 21
102000028180 Glycophorins Human genes 0.000 claims description 20
108091005250 Glycophorins Proteins 0.000 claims description 20
235000018102 proteins Nutrition 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 18
239000004471 Glycine Substances 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 17
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 17
235000018417 cysteine Nutrition 0.000 claims description 17
239000000427 antigen Substances 0.000 claims description 16
102000036639 antigens Human genes 0.000 claims description 16
108091007433 antigens Proteins 0.000 claims description 16
210000003617 erythrocyte membrane Anatomy 0.000 claims description 16
230000015572 biosynthetic process Effects 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
238000005406 washing Methods 0.000 claims description 14
239000000463 material Substances 0.000 claims description 12
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 11
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
239000004473 Threonine Chemical group 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 10
239000003431 cross linking reagent Substances 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
229940124597 therapeutic agent Drugs 0.000 claims description 8
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
150000001720 carbohydrates Chemical class 0.000 claims description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
230000001268 conjugating effect Effects 0.000 claims description 5
239000003527 fibrinolytic agent Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 5
229960000103 thrombolytic agent Drugs 0.000 claims description 5
239000012216 imaging agent Substances 0.000 claims description 4
230000003834 intracellular effect Effects 0.000 claims description 4
108020004707 nucleic acids Proteins 0.000 claims description 4
102000039446 nucleic acids Human genes 0.000 claims description 4
235000003704 aspartic acid Nutrition 0.000 claims description 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
101710138657 Neurotoxin Proteins 0.000 claims description 2
229940127089 cytotoxic agent Drugs 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
229910001385 heavy metal Inorganic materials 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
238000002595 magnetic resonance imaging Methods 0.000 claims description 2
239000002581 neurotoxin Substances 0.000 claims description 2
231100000618 neurotoxin Toxicity 0.000 claims description 2
239000003900 neurotrophic factor Substances 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 6
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
239000000539 dimer Substances 0.000 claims 2
239000000178 monomer Substances 0.000 claims 2
DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical group SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
210000001772 blood platelet Anatomy 0.000 description 263
239000011324 bead Substances 0.000 description 143
230000004520 agglutination Effects 0.000 description 83
210000004623 platelet-rich plasma Anatomy 0.000 description 62
238000006243 chemical reaction Methods 0.000 description 53
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 50
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 50
230000003993 interaction Effects 0.000 description 50
239000000872 buffer Substances 0.000 description 47
102000005962 receptors Human genes 0.000 description 41
108020003175 receptors Proteins 0.000 description 41
108010049003 Fibrinogen Proteins 0.000 description 40
102000008946 Fibrinogen Human genes 0.000 description 40
238000002474 experimental method Methods 0.000 description 40
229940012952 fibrinogen Drugs 0.000 description 40
210000004027 cell Anatomy 0.000 description 38
239000000243 solution Substances 0.000 description 37
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
238000003556 assay Methods 0.000 description 33
102100025306 Integrin alpha-IIb Human genes 0.000 description 31
101710149643 Integrin alpha-IIb Proteins 0.000 description 31
230000000694 effects Effects 0.000 description 23
208000032843 Hemorrhage Diseases 0.000 description 22
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
230000001965 increasing effect Effects 0.000 description 21
239000004971 Cross linker Substances 0.000 description 19
238000002360 preparation method Methods 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000010168 coupling process Methods 0.000 description 18
238000005859 coupling reaction Methods 0.000 description 18
239000006228 supernatant Substances 0.000 description 18
230000008878 coupling Effects 0.000 description 17
230000006870 function Effects 0.000 description 17
238000005534 hematocrit Methods 0.000 description 17
230000005764 inhibitory process Effects 0.000 description 17
210000002381 plasma Anatomy 0.000 description 17
239000000523 sample Substances 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 17
238000004220 aggregation Methods 0.000 description 16
125000003277 amino group Chemical group 0.000 description 16
239000011780 sodium chloride Substances 0.000 description 16
FRUFOUVTWCKBKQ-UHFFFAOYSA-M sodium;4-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC(S([O-])(=O)=O)=CC=C1OC(=O)CCCCCN1C(=O)C=CC1=O FRUFOUVTWCKBKQ-UHFFFAOYSA-M 0.000 description 16
229920005989 resin Polymers 0.000 description 15
239000011347 resin Substances 0.000 description 15
238000001727 in vivo Methods 0.000 description 14
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 description 13
230000003247 decreasing effect Effects 0.000 description 13
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
239000011734 sodium Substances 0.000 description 13
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
238000001994 activation Methods 0.000 description 12
239000012530 fluid Substances 0.000 description 12
239000000499 gel Substances 0.000 description 12
108010035532 Collagen Proteins 0.000 description 11
102000008186 Collagen Human genes 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
QZAYGJVTTNCVMB-UHFFFAOYSA-N Serotonin Natural products C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 11
208000007536 Thrombosis Diseases 0.000 description 11
239000007983 Tris buffer Substances 0.000 description 11
229920001436 collagen Polymers 0.000 description 11
230000021615 conjugation Effects 0.000 description 11
239000008103 glucose Substances 0.000 description 11
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
230000001464 adherent effect Effects 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
125000005647 linker group Chemical group 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
230000004913 activation Effects 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
238000011534 incubation Methods 0.000 description 9
239000012071 phase Substances 0.000 description 9
230000010118 platelet activation Effects 0.000 description 9
229910019142 PO4 Inorganic materials 0.000 description 8
238000004132 cross linking Methods 0.000 description 8
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
239000010452 phosphate Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
239000001509 sodium citrate Substances 0.000 description 8
208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
206010018910 Haemolysis Diseases 0.000 description 7
238000013459 approach Methods 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
230000008588 hemolysis Effects 0.000 description 7
239000003446 ligand Substances 0.000 description 7
239000002502 liposome Substances 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
229940076279 serotonin Drugs 0.000 description 7
238000003756 stirring Methods 0.000 description 7
230000003582 thrombocytopenic effect Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 7
229940038773 trisodium citrate Drugs 0.000 description 7
NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 6
102000009027 Albumins Human genes 0.000 description 6
108010088751 Albumins Proteins 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
235000014633 carbohydrates Nutrition 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000007423 decrease Effects 0.000 description 6
102000006495 integrins Human genes 0.000 description 6
108010044426 integrins Proteins 0.000 description 6
229910001629 magnesium chloride Inorganic materials 0.000 description 6
230000003204 osmotic effect Effects 0.000 description 6
230000007017 scission Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 5
239000004743 Polypropylene Substances 0.000 description 5
108090000190 Thrombin Proteins 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
230000004523 agglutinating effect Effects 0.000 description 5
238000007818 agglutination assay Methods 0.000 description 5
239000003146 anticoagulant agent Substances 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000001276 controlling effect Effects 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
150000002148 esters Chemical group 0.000 description 5
150000002333 glycines Chemical class 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
229920002239 polyacrylonitrile Polymers 0.000 description 5
229920001155 polypropylene Polymers 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
229960004072 thrombin Drugs 0.000 description 5
ARNGIGOPGOEJCH-KKUMJFAQSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ARNGIGOPGOEJCH-KKUMJFAQSA-N 0.000 description 4
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
229930182837 (R)-adrenaline Natural products 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
239000004475 Arginine Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
102000004856 Lectins Human genes 0.000 description 4
108090001090 Lectins Proteins 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 4
102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 4
241000700159 Rattus Species 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
229960005139 epinephrine Drugs 0.000 description 4
125000004185 ester group Chemical group 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000002523 lectin Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
238000005580 one pot reaction Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
150000003573 thiols Chemical group 0.000 description 4
206010043554 thrombocytopenia Diseases 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 3
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical group C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
235000019743 Choline chloride Nutrition 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
102100022337 Integrin alpha-V Human genes 0.000 description 3
WZKXBGJNNCGHIC-UHFFFAOYSA-N Leucomalachite green Chemical compound C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)C)C1=CC=CC=C1 WZKXBGJNNCGHIC-UHFFFAOYSA-N 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108060008245 Thrombospondin Proteins 0.000 description 3
102000002938 Thrombospondin Human genes 0.000 description 3
208000024248 Vascular System injury Diseases 0.000 description 3
208000012339 Vascular injury Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
108010048673 Vitronectin Receptors Proteins 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 3
108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
229960003178 choline chloride Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000000284 extract Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
108010060000 trigramin Proteins 0.000 description 3
HIQYTCYQOKMFPP-WNQIDUERSA-N (2r)-2-amino-3-sulfanylpropanoic acid;pyrrole-2,5-dione Chemical compound SC[C@H](N)C(O)=O.O=C1NC(=O)C=C1 HIQYTCYQOKMFPP-WNQIDUERSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
206010060935 Alloimmunisation Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
208000035049 Blood-Borne Infections Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
239000007990 PIPES buffer Substances 0.000 description 2
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
AXIKDPDWFVPGOD-UHFFFAOYSA-O [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;2-(2,4,5,7-tetrabromo-3,6-dihydroxyxanthen-10-ium-9-yl)benzoic acid Chemical compound C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21.OC(=O)C1=CC=CC=C1C1=C(C=C(Br)C(O)=C2Br)C2=[O+]C2=C1C=C(Br)C(O)=C2Br AXIKDPDWFVPGOD-UHFFFAOYSA-O 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
108010056970 arginyl-glycyl-aspartic acid directed cell adhesion receptor Proteins 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
239000013068 control sample Substances 0.000 description 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
230000003861 general physiology Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
125000004997 halocarbonyl group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
230000002439 hemostatic effect Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000007654 immersion Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000002934 lysing effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
239000004474 valine Substances 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
MDNRBNZIOBQHHK-KWBADKCTSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N MDNRBNZIOBQHHK-KWBADKCTSA-N 0.000 description 1
NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
VHYRLCJMMJQUBY-UHFFFAOYSA-N 1-[4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC1=CC=C(N2C(C=CC2=O)=O)C=C1 VHYRLCJMMJQUBY-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
241000132092 Aster Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
101710126496 Envelope glycoprotein I Proteins 0.000 description 1
108010012088 Fibrinogen Receptors Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
102100031574 Platelet glycoprotein 4 Human genes 0.000 description 1
101710202087 Platelet glycoprotein 4 Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000702660 Rice gall dwarf virus Species 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
244000078885 bloodborne pathogen Species 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004139 eicosanoid metabolism Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
229940093476 ethylene glycol Drugs 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000007392 microtiter assay Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
231100001223 noncarcinogenic Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000016446 peptide cross-linking Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003805 potassium influx Effects 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
231100000175 potential carcinogenicity Toxicity 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
230000005588 protonation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000011435 rock Substances 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
CKYLHMGDNIAAPE-UHFFFAOYSA-M sodium;4-hydroxy-3-nitrobenzenesulfonate Chemical compound [Na+].OC1=CC=C(S([O-])(=O)=O)C=C1[N+]([O-])=O CKYLHMGDNIAAPE-UHFFFAOYSA-M 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008054 sulfonate salts Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Virology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Botany (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU90588/91A 1990-11-09 1991-11-12 Erythrocytes and thrombo-erythrocytes as target specific agents Ceased AU651643B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61116490A	1990-11-09	1990-11-09
US611164		1990-11-09
PCT/US1991/008430 WO1992008804A1 (en)	1990-11-09	1991-11-12	Erythrocytes and thrombo-erythrocytes as target specific agents

Publications (2)

Publication Number	Publication Date
AU9058891A AU9058891A (en)	1992-06-11
AU651643B2 true AU651643B2 (en)	1994-07-28

Family

ID=24447889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU90588/91A Ceased AU651643B2 (en)	1990-11-09	1991-11-12	Erythrocytes and thrombo-erythrocytes as target specific agents

Country Status (7)

Country	Link
EP (1)	EP0558645A4 (fi)
JP (1)	JPH06504535A (fi)
KR (1)	KR930702341A (fi)
AU (1)	AU651643B2 (fi)
CA (1)	CA2095925A1 (fi)
FI (1)	FI932114A (fi)
WO (1)	WO1992008804A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6521594B1 (en)	1990-04-06	2003-02-18	La Jolla Cancer Research Foundation	Method and composition for treating thrombosis
US5672585A (en) *	1990-04-06	1997-09-30	La Jolla Cancer Research Foundation	Method and composition for treating thrombosis
US6017877A (en) *	1990-04-06	2000-01-25	La Jolla Cancer Research Foundation	Method and composition for treating thrombosis
US5780303A (en) *	1990-04-06	1998-07-14	La Jolla Cancer Research Foundation	Method and composition for treating thrombosis
GB9705787D0 (en)	1997-03-20	1997-05-07	Thrombosis Res Inst	Modified dendroaspins
JP2002500168A (ja) *	1998-01-06	2002-01-08	トラステイーズ・オブ・ボストン・ユニバーシテイ	装飾赤血球
DE10038900A1 (de) *	2000-08-09	2002-03-07	Haemosys Gmbh	Einfache Methode zum drug monitoring von GPIIb/IIIa-Rezeptor-Antagonisten
US7195919B2 (en) *	2003-12-19	2007-03-27	Beckman Coulter, Inc.	Hematology controls for reticulocytes and nucleated red blood cells
DE102004054536A1 (de) *	2004-11-06	2006-05-11	Capsulution Nanoscience Ag	Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
JP2009523787A (ja) *	2006-01-19	2009-06-25	アイジーンインコーポレイテッド	ペプチドを有効成分とする血管関連疾患の治療剤組成物
EP1849482A1 (en) *	2006-04-25	2007-10-31	Capsulution Nanoscience AG	Multimodally altered cells as a form for administering active substances and as diagnostic particles
KR100824396B1 (ko) *	2006-10-10	2008-04-22	(주)케어젠	상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도
CN101625267B (zh) *	2008-07-11	2011-07-20	财团法人工业技术研究院	热侦测系统及其侦测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377567A (en) *	1978-10-02	1983-03-22	The Procter & Gamble Company	Lipid membrane drug delivery
DE3218121A1 (de) *	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
US4792525A (en) *	1982-08-04	1988-12-20	La Jolla Cancer Research Foundation	Tetrapeptide
US4988621A (en) *	1985-05-24	1991-01-29	La Jolla Cancer Research Foundation	Peptides in cell detachment and aggregation
JPS62190129A (ja) *	1986-02-18	1987-08-20	Green Cross Corp:The	制癌剤含有マイクロキヤリアの製造方法
US5000960A (en) *	1987-03-13	1991-03-19	Micro-Pak, Inc.	Protein coupling to lipid vesicles

1991
- 1991-11-12 AU AU90588/91A patent/AU651643B2/en not_active Ceased
- 1991-11-12 JP JP4502274A patent/JPH06504535A/ja active Pending
- 1991-11-12 CA CA002095925A patent/CA2095925A1/en not_active Abandoned
- 1991-11-12 WO PCT/US1991/008430 patent/WO1992008804A1/en not_active Application Discontinuation
- 1991-11-12 EP EP19920901253 patent/EP0558645A4/en not_active Withdrawn
- 1991-11-12 KR KR1019930701399A patent/KR930702341A/ko not_active Application Discontinuation
1993
- 1993-05-10 FI FI932114A patent/FI932114A/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR930702341A (ko)	1993-09-08
FI932114A0 (fi)	1993-05-10
JPH06504535A (ja)	1994-05-26
EP0558645A4 (en)	1994-07-06
WO1992008804A1 (en)	1992-05-29
AU9058891A (en)	1992-06-11
EP0558645A1 (en)	1993-09-08
FI932114A (fi)	1993-07-01
CA2095925A1 (en)	1992-05-10

Publication	Publication Date	Title
US5328840A (en)	1994-07-12	Method for preparing targeted carrier erythrocytes
Coller et al.	1992	Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions.
Vogt et al.	1982	Interaction of cationized antigen with rat glomerular basement membrane: In situ immune complex formation
JP3926839B2 (ja)	2007-06-06	万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5110730A (en)	1992-05-05	Human tissue factor related DNA segments
AU651643B2 (en)	1994-07-28	Erythrocytes and thrombo-erythrocytes as target specific agents
JP3487849B2 (ja)	2004-01-19	自己免疫性を改善せしめるうえで有用なｍｈｃコンジュゲート
CA2000048A1 (en)	1990-04-03	Peptides and antibodies that inhibit integrin-ligand bindin g
JP3315405B2 (ja)	2002-08-19	レセプター誘発結合部位に対するモノクローナル抗体
US5763585A (en)	1998-06-09	Method of making MHC-peptide complexes using metal chelate affinity chromatography
JP2846470B2 (ja)	1999-01-13	Ｈｌａペプチドによるリンパ球活性の調節
EP0661985B1 (en)	1999-07-07	Peptides capable of binding cd8 molecules on ctl precursors
JP2011184465A (ja)	2011-09-22	止血を促進するためのフィブリノゲン標的微粒子
JP2004528025A (ja)	2004-09-16	修飾されたアネキシン蛋白質及び血栓症を防ぐための方法
JP2007507480A5 (fi)	2007-11-22
JPH10511954A (ja)	1998-11-17	抗炎症ｃｄ１４ペプチド
JP2005511017A (ja)	2005-04-28	ホーミングペプチド
JP2001511762A (ja)	2001-08-14	選択性スロンビン抑制剤としてのブラジキニン同族体
US20080241233A1 (en)	2008-10-02	Targeted delivery and expression of procoagulant hemostatic activity
CA2139735A1 (en)	1994-01-20	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
Fu et al.	1994	Immunocytochemical localization of M2 muscarinic receptors in rat ventricles with anti-peptide antibodies.
EP0333517A2 (en)	1989-09-20	Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
WO1993016712A1 (en)	1993-09-02	MUTANT GPIbα FRAGMENTS AND RECOMBINANT EXPRESSION THEREOF
JP3715313B2 (ja)	2005-11-09	ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用
CA2201519A1 (en)	1996-04-11	Preparation of mhc-peptide complexes